ProQR Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PRQR and other ETFs, options, and stocks.

About PRQR

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. 

CEO
Daniel Anton de Boer
CEODaniel Anton de Boer
Employees
187
Employees187
Headquarters
Leiden, Zuid-Holland
HeadquartersLeiden, Zuid-Holland
Founded
2012
Founded2012
Employees
187
Employees187

PRQR Key Statistics

Market cap
178.56M
Market cap178.56M
Price-Earnings ratio
-3.89
Price-Earnings ratio-3.89
Dividend yield
Dividend yield
Average volume
367.72K
Average volume367.72K
High today
$1.77
High today$1.77
Low today
$1.66
Low today$1.66
Open price
$1.73
Open price$1.73
Volume
90.72K
Volume90.72K
52 Week high
$3.10
52 Week high$3.10
52 Week low
$1.07
52 Week low$1.07

Stock Snapshot

With a market cap of 178.56M, ProQR Therapeutics(PRQR) trades at $1.70. The stock has a price-to-earnings ratio of -3.89.

On 2026-03-18, ProQR Therapeutics(PRQR) stock moved within a range of $1.66 to $1.77. With shares now at $1.70, the stock is trading +2.0% above its intraday low and -4.2% below the session's peak.

Trading activity shows a volume of 90.72K, compared to an average daily volume of 367.72K.

Over the past 52 weeks, ProQR Therapeutics(PRQR) stock has traded between a high of $3.10 and a low of $1.07.

Over the past 52 weeks, ProQR Therapeutics(PRQR) stock has traded between a high of $3.10 and a low of $1.07.

PRQR News

TipRanks 5d
ProQR Therapeutics Faces Heightened Activist Investor Pressure and Governance Uncertainty

ProQR Therapeutics BV (PRQR) has disclosed a new risk, in the Share Price & Shareholder Rights category. ProQR Therapeutics BV faces heightened risk from stock...

TipRanks 6d
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027

ProQR ( (PRQR) ) just unveiled an update. On March 12, 2026, ProQR reported its operating and financial results for the year ended Dec. 31, 2025, highlighting...

TipRanks 6d
ProQR Therapeutics assumed with an Outperform at Oppenheimer

Oppenheimer analyst Kostas Biliouris assumed coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $9 price target The firm sees a lot to like for...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

More PRQR News

TipRanks 6d
ProQR Therapeutics reports FY25 EPS vs last year

At December 31, 2025, ProQR held cash and cash equivalents of approximately EUR 92.4 million, compared to EUR 149.4 million at December 31, 2024. “2025 was a ye...

People also own

Based on the portfolios of people who own PRQR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.